Atlas market file · Equity · United States
Supernus Pharmaceuticals, Inc.SUPN
- Last close
- 46.76
- Change
- -0.32%
- 96-bar range
- 42.45 – 52.96
- As of
- 6 Aug 2026
Supernus Pharmaceuticals, Inc. is a pharmaceutical preparations issuer listed as SUPN on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
SUPN
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+33.71% over the window).
Source rail: Yahoo Finance chart API (SUPN). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for SUPN. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
SUPN public profile
Pharmaceutical preparations issuer. Supernus Pharmaceuticals, Inc. is connected to current market context, cited company sources and its retained research file.
Supernus Pharmaceuticals, Inc. trades as SUPN on NASDAQ. Supernus Pharmaceuticals, Inc. (SUPN) has a latest verified close of 46.76, down 0.32%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files SUPN under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Supernus Pharmaceuticals, Inc. today
Supernus Pharmaceuticals (SUPN) opened the week with a Q1 2026 report card that read like a medical chart in decline: $207.7M revenue but a $2.3M net loss, $39.4M burned in R&D, and inventory piling up like expired pills at $110.8M. The company’s latest 10-Q filing shows operating income cratered to -$8.3M, a hole deep enough to make even a bond trader prescribe bed rest. (source: SEC EDGAR)
Supernus’s business model hinges on neuroscience drugs for conditions like major depressive disorder (MDD), with partner Shionogi launching a zuranolone-based product in Japan earlier this year. Yet the financials tell a different story: cash flow from operations barely covers R&D, and the company’s $423.9M liabilities loom over $184.9M cash reserves. The recent S-8 filing to register 4M new shares suggests Supernus is betting on dilution as a growth strategy-or perhaps a Hail Mary pass to fund its next phase of 'innovation.' (source: Our Products, SEC EDGAR)
While the company’s social media guidelines warn users to report adverse effects from its medications, investors might want to flag their own symptoms: share dilution, negative earnings, and a balance sheet that’s more Band-Aid than breakthrough. The May 5th 8-K confirmed a conference call to discuss results, which given the numbers, should come with a free stress test. (source: SEC EDGAR, Social Media Guidelines)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
SUPN technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on SUPN
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep SUPN research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
SUPN FAQ
What is Supernus Pharmaceuticals, Inc. (SUPN)?Supernus Pharmaceuticals, Inc. (SUPN) has a latest verified close of 46.76, down 0.32%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Supernus Pharmaceuticals, Inc. (SUPN) has a latest verified close of 46.76, down 0.32%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for SUPN?Supernus Pharmaceuticals, Inc. (SUPN) has a latest verified close of 46.76, down 0.32%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
Supernus Pharmaceuticals, Inc. (SUPN) has a latest verified close of 46.76, down 0.32%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files SUPN under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the SUPN page updated?The SUPN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The SUPN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for SUPN?The SUPN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:SUPN. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The SUPN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:SUPN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on SUPN?Yes. The workstation can open SUPN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open SUPN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this SUPN page investment advice?No. The SUPN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The SUPN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →